In Depth - Pharma Technology Focus | Issue 127

Go to article: Home | CRISPR gene therapies cut through in 2023

Go to article: In this issue

Go to article: Contents

Go to article: Mimotopes Company Insight

Go to article: Tripletree

Go to article: Briefing

Go to article: Industry news

Go to article: The pharma industry briefing

Go to article: HOF Sonderanlagenbau

Go to article: Owen Mumford Company Insight

Go to article: Owen Mumford Aidaptus

Go to article: Comment

Go to article: High hopes for mRNA anti-cancer vaccines with early successes

Go to article: Cell therapies might revolutionise treatment for multiple sclerosis patients

Go to article: Downturn for top biopharma companies as Covid-19 vaccine demand falls in Q3

Go to article: Inflation threatens supply of life-saving generics to Europe

Go to article: Data is the key to a safer and more controlled pharmaceutical cold-chain

Go to article: Molnar-Institute Company Insight

Go to article: Molnar-Institute

Go to article: In Depth

Go to article: CRISPR gene therapies: Is 2023 a milestone year in the making?

Go to article: Tracking the ups and downs of pharma deals

Go to article: Regulation starts to catch up with AI in pharma

Go to article: Next on trial diversity: Embracing participants with cognitive impairment

Go to article: Digital twins: The next frontier to ease clinical trial conduct

Go to article: CMO Moves: Regulatory catalysts for therapy manufacturing -January

Go to article: Events

Go to article: Next issue

CRISPR gene therapies: Is 2023 a milestone year in the making?